KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, available for order at Biologics, Inc.

CARY, N.C. (March 17, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Novartis to be a specialty pharmacy provider for KISQALI® (ribociclib).
Source: McKesson News - Category: Information Technology Source Type: news